EFFECT OF ORAL ADMINISTRATION OF MICROENCAPSULATED LACTIC ACID BACTERIA IN A METABOLIC SYNDROME MURINE MODEL

RUSSO, MATIAS IRINEO; MARQUEZ, ANTONELA; ABEIJON MUKDSI, MARIA CLAUDIA; SANTACRUZ, ARLETTE; LOPEZ-MALO, AURELIO; GAUFFIN CANO, MARIA PAOLA; MEDINA, ROXANA BEATRIZ

San Miguel de Tucumán

Simposio; V Simposio Internacional de Bacterias Lácticas; 2016

Centro de Referencia para Lactobacilos (CERELA)-CONICET

Metabolic syndrome (MS) is a termused in recent years for a group of risk factors including visceral obesity,hypertension, hyperglycemia and atherogenic dyslipidemia, which predispose theindividual to develop cardiovascular disease and type 2 diabetes. Feruloylesterases (FE) are enzymes that catalize the hydrolytic release of ferulic acid(FA), present in vegetable foods. FA is a phenolic acid with provenantioxidant, hypoglycemic and lipid lowering activities. Lactobacillus fermentum CRL1446 (Lf CRL1446) and Lactobacillusjohnsonii CRL1231 (Lj CRL1231)are potential probiotic strains selected for their FE activity capable ofreleasing FA in vitro. Theadministration of lactic acid bacteria (LAB) with FE activity could improvemetabolic markers present in animal models of MS. The aim of the present workwas to evaluate the effect of oral administration of spray-dried microcapsulescontaining Lf CRL1446 or Lj CRL1231 on metabolic markers in amice model of MS. Six week old male Swiss albino mice were divided into sixgroups (n = 6, each) and daily fed for a period of 7 weeks with a standard diet(control group) and a hyperlipidemic diet (MS group). Mice received by gavagethree types of microcapsules: I) empty (non-treated group), II) containing Lf CRL1446 (Lf group) or III) containing LjCRL1231 (Lj group). Theadministration dose was 107 CFU/day/mouse. Animals were sacrificedat week 7. Adiposity index was calculated. FE activity was determined in gutcontent using methyl ferulate as substrate. Released FA was detected by HPLC.Animal metabolic status was evaluated by determination of plasmatic glucoseconcentration and lipid profile (total cholesterol, HDL-cholesterol,LDL-cholesterol, triglycerides). Results showed that body weight gain washigher after 7 weeks in mice from MS group, which presented an adiposity indexsignificantly higher than that from control group, whereas no significantdifferences were observed among the three groups receiving microcapsules. Totalintestinal FE activity showed ~1.2 fold increase in mice receivingmicroencapsulated LAB compared to non-treated group. Plasmatic levels offasting glucose were higher in MS group compared to control group, and asignificant decrease in Lf group wasobserved compared to non-treated mice. A significant reduction in the levels oftotal cholesterol, LDL-cholesterol and triglycerides in Lf and Lj groups was alsoobserved. According to these results, oral administration of spray-driedmicrocapsules containing Lf CRL1446and Lj CRL1231 increases intestinalFE activity and induces beneficial metabolic changes for prevention/treatmentof MS.